Navigation Links
Medizone International Announces Third Round of AsepticSure
Date:10/14/2009

SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that a third round of AsepticSure(TM) trials have begun at Innovation Park, Queen's University. Building on the results obtained during the first and second round of laboratory testing, this third round is being conducted to establish the precise protocols necessary in order to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. Simultaneously, a development prototype is being finalized in order to conduct a full room scale hospital mock up.

Medizone's CEO Edwin Marshall stated, "While this stage of the development program has taken a bit longer than we envisioned, we expect the results to be well worthwhile. It is now clear the integration of technology involved, combined with the scientific data that continues to be gathered, should not only establish Medizone's AsepticSure(TM) system as the global standard for hospital and infrastructure decontamination, but with additional state of the art interlocking patent opportunities being developed, should offer the company exceedingly strong patent protection for this emerging technology."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. The trial program has been expanded in final preparation for a hospital mock-up, intended to be followed by hospital beta testing. It is estimated hospitals deploying the AsepticSure(TM) system will save $6 to $7 for each $1 invested while preventing tens of thousands of hospital acquired infections.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

           Investor Relations: 415-868-0300 / web site: www.medizoneint.com
                        E-mail: operations@medizoneint.com

SOURCE Medizone International, Inc.


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... May 4, 2016 Research and ... Cancer Stem Cell Therapy Market Outlook 2020" report ... ) , ,Recombinant technology has improved significantly in ... to be developed in coming years. Many cancer drugs ... stem cell therapies are also expected to be developed ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... community enrichment program serving families of greater Dubuque, IA. The current campaign fundraises ... and honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made ...
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and ... today announced a new partnership to reach nearly 1 million children with important water ... instant and is the leading cause of accidental death in children one to 6 ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Drago presented a talk highlighting the organization’s successful Care Transitions program ... , The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer ... Pittman, along with his university coaching staff. Together they bring their winning Vandals coaching ... run for youth players ages 5-13, and high school players. Session dates are as ...
Breaking Medicine News(10 mins):